Recent articles

Top Advances

While we look back on 2024, we can reflect upon the incredible progress we’ve made in advancing breakthroughs toward cures and improving everyday life with T1D.   This wouldn’t have been possible without each and every one of you and your continued support of our mission as we drive toward cures for T1D.   Here are the […]

A novel immune therapy called tegoprubart made by Eledon Pharmaceuticals and being tested in kidney transplant patients has the potential to help beta cell transplants survive in people with type 1 diabetes (T1D) with fewer side effects. The first data from this Breakthrough T1D-funded study suggests it does. The study was presented at the 5th […]

At the 2024 International Society for Pediatric and Adolescent Diabetes (ISPAD) Conference in Lisbon, Portugal, the world’s leading diabetes researchers, academics, and members of industry gathered to share the latest and greatest in diabetes research. Breakthrough T1D leaders and many of our funded researchers and collaborators were on hand —for ISPAD’s 50th birthday—to share new […]

It’s early October, which means the Nobel Prizes are being awarded in several categories. These prestigious awards recognize outstanding contributions in Peace, Literature, Physics, Chemistry, Physiology or Medicine, and Economic Sciences. They go to the best and brightest people with the best and brightest ideas. This year, the prizes recognize work that is, in several […]

Young woman with type 1 diabetes and continuous glucose monitor

There is currently no cure for type 1 diabetes (T1D), but Breakthrough T1D has a strategy to change this and transform the future for everyone with T1D.

Press releases

Read the latest press releases and statements from Breakthrough T1D.

Get the Latest T1D Updates

Sign up for our monthly mission progress newsletter, The Pipeline, to stay up to date on everything you need to know about T1D, from research to advocacy, to clinical care – and everything in between.

  • This field is for validation purposes and should be left unchanged.